

主 管:

湖南省卫生健康委员会

主 办:

湖南省肿瘤医院

学术顾问:

孙 燕 周宏灏 甄永苏

马 军 王忠民 杨汉煜

梅建明 霍仕文

编委会主任:

向 华

名誉主编:

任华益

主 编:

王 静

副主编:

董晓荣 廖前进 刘昭前

欧阳取长 向 阳 杨 农

杨小平 张会来 周 辉

编辑部主任:

王 静

编 辑:

董珊珊 房 超 李 征

刘 颖 于 静

责任编辑:

王 娟

出 版:

《肿瘤药 学》编辑部

国内发行:

湖南省报刊发行局

邮发代号: 42-391

国外发行:

中国国际图书贸易集团有限公司

(北京399信箱, 100048)

代号: BM2809

目 录

指南·规范·共识

肿瘤科无痛病房管理规范专家共识

邱翠玲, 李旭英, 欧阳取长, 等 145

抗实体瘤小分子靶向药物基础研究与临床实践专栏

MDMX: 结构、功能、调控及其抑制剂的研究进展

刘书琪, 王洪波 152

DNA聚合酶 θ 的生物学特性及其小分子抑制剂在肿瘤中的研究进展

张 瑶, 王 娟, 李 敏, 等 161

新型KRAS突变体抑制剂抗胰腺癌的作用研究

罗桂芳, 陈 攀, 刘晓雨, 等 169

一种新型克唑替尼纳米药物制剂的制备及其体外抗非小细胞肺癌研究

刘泓池, 罗 迁, 刘 熠, 等 178

氯胍联合奥希替尼抑制膀胱癌细胞的增殖和迁移

王伟帆, 周晓辰, 谢宜君, 等 187

综述

小细胞肺癌化疗及免疫治疗耐药机制的研究进展

米克日阿依·艾合买提, 帕提古力·阿尔西丁, 刘俊远 197

铂类药物溶媒要求差异性原因分析

刘 馨, 邱益琼, 夏 雷 205

基础研究

基于网络药理学及实验验证分析二至丸抗肝纤维化的作用机制

钟晓宇, 李 懿, 陈星梅, 等 211

临床研究

深部热疗联合恩度及nab-PC方案治疗驱动基因阴性且PD-L1表达阴性的晚期肺鳞癌的临床研究

周红梅, 肖 敬, 李 超, 等 221

谷胱甘肽过氧化物酶4调控结肠癌铁死亡的作用机制及其对预后的影响

肖 丹, 向春红, 伍 磊, 等 229

以奥妥珠单抗为基础的联合方案治疗B细胞非霍奇金淋巴瘤的临床综合评价

赵新才, 宋陆茜, 陈 娟, 等 237

SH/ALB对接受阿片类药物和免疫治疗的NSCLC患者预后的预测价值

雷 雁, 刘 勇 245

基于倾向性评分匹配的PD-1抑制剂相关甲状腺不良事件危险因素分析

汪祝青, 吴怡青, 朱忠华 252

索拉非尼联合阿扎胞苷+低剂量CHG方案治疗难治复发FLT3-ITD阳性AML的临床疗效观察

任欣欣, 韩晓辉, 赵洪波, 等 259

中国标准连续出版物号:

ISSN 2095-1264
CN 43-1507/R

商标注册证号:

6125707

印刷:

长沙美银印务广告有限公司

邮购:

《肿瘤药学》编辑部(长沙市岳麓
区咸嘉湖路582号湖南省肿瘤医院,
邮编:410013)

(本刊发行部全年办理补订手续)

电话:

0731-89762609

网址:

<http://www.zgzlyx.com>

中国知网优先数字出版网址:

<http://www.cnki.net>

邮箱:

zgzlyx2011@163.com

微信服务号:

肿瘤药学杂志

定价:

每本30元, 全年180元

出版日期:

2025年4月28日

期刊基本参数:

CN 43-1507/R*2011*B*A4*144*
ZH*P*¥30.00*19*2025-4

病例报道

安罗替尼联合AK105治疗一线复发的小细胞肺癌1例

..... 毕文欣, 杜超, 李成林 264

不同分子亚型同时性原发性双侧乳腺癌合并骨转移1例

..... 黄小辉, 唐林, 周围, 等 269

肿瘤护理

IMB干预模式对芳香化酶抑制剂治疗绝经后乳腺癌患者继发骨质疏松的影响
研究

..... 张格林, 吴玮, 孙园, 等 275

基于GLIM标准与PG-SGA的结直肠癌患者术前营养评估诊断一致性研究:一
项前瞻性队列分析

..... 孙未, 陈鹏超, 罗越, 等 283

本刊版权归《肿瘤药学》编辑部
所有, 如有印刷质量问题请向编辑部
申请更换。

Administrative Office:

Health Commission of Hunan Province

Sponsored by:

Hunan Cancer Hospital

Academic Advisor:

SUN Yan, ZHOU Honghao,
ZHEN Yongsu, MA Jun,
WANG Zhongmin, YANG Hanyu,
MEI Jianming, HUO Shiwen

Chief of Editorial Board:

XIANG Hua

Honorary Editor-in-Chief:

REN Huayi

Editor-in-Chief:

WANG Jing

Deputy Editor-in-Chief:

DONG Xiaorong, LIAO Qianjin,
LIU Zhaoqian, OUYANG Quchang,
XIANG Yang, YANG Nong,
YANG Xiaoping, ZHANG Huilai,
ZHOU Hui

Director of Editorial Department:

WANG Jing

Editor:

DONG Shanshan, FANG Chao,
LI Zheng, LIU Ying, YU Jing

Editor in Charge:

WANG Juan

Publication:

Editorial Department of *Anti-tumor
Pharmacy*

Domestic Distributor:

Hunan Bureau for Distribution of
Newspaper and Periodicals
Code No. 42-391

Overseas Distributor:

China International Book Trading
Corporation (P.O. Box 399, Beijing,
100048, China)
Code No. BM2809

CONTENTS

Guide · Standard · Consensus

Expert consensus on standardized management guidelines for pain-free wards in oncology departments
..... QIU Cuiling, LI Xuying, OUYANG Quchang, et al. 145

Special Column on Basic Research and Clinical Practice of Anti-Solid Tumor Small Molecule Targeted Drugs

MDMX: advances in structure, function, regulation and its inhibitors
..... LIU Shuqi, WANG Hongbo 152

The biological characteristics of DNA polymerase θ and its small molecule inhibitors research progress in tumors
..... ZHANG Yao, WANG Juan, LI Min, et al. 161

Study on the effects of novel KRAS mutant inhibitors on pancreatic cancer
..... LUO Guifang, CHEN Pan, LIU Xiaoyu, et al. 169

Design and development of a novel crizotinib nanoformulation: in vitro investigation of its antitumor efficacy against non-small cell lung cancer
..... LIU Hongchi, LUO Qian, LIU Yi, et al. 178

The combination of proguanil and osimertinib inhibits the proliferation and migration of bladder cancer cells
..... WANG Weifan, ZHOU Xiaochen, XIE Yijun, et al. 187

Review

Research progress on the mechanisms of chemotherapy and immunotherapy resistance in small cell lung cancer
..... AIHEMAITI Mikeriayi, AERXIDING Patiguli, LIU Junyuan 197

Analysis of the causes for variation in solvent selection of platinum-based drugs
..... LIU Xin, QIU Yiqiong, XIA Lei 205

Basic Research

Network pharmacology and experimental validation analysis of the anti-liver fibrosis mechanisms of Erzhi pill
..... ZHONG Xiaoyu, LI Yi, CHEN Xingmei, et al. 211

Clinical Research

Clinical study of deep hyperthermia combined with Endostar and nab-PC regimen in the treatment of driver gene-negative and PD-L1 expression-negative advanced lung squamous cell carcinoma
..... ZHOU Hongmei, XIAO Jing, LI Chao, et al. 221

The mechanisms of glutathione peroxidase 4 in regulating ferroptosis in colon cancer and its impact on prognosis
..... XIAO Dan, XIANG Chunhong, WU Lei, et al. 229

Comprehensive clinical evaluation of obinutuzumab-based regimen in treatment of B-cell non-Hodgkin lymphoma
..... ZHAO Xincui, SONG Luxi, CHEN Juan, et al. 237

China Standard Serial Numbering:

ISSN 2095-1264
CN 43-1507/R

Trademark Registration:

6125707

Printing:

Changsha Fuyin Printing and Advertising Co., Ltd.

Post Address:

Editorial Department of *Anti-tumor
Pharmacy* (No.582 Xianjiahu Road,
Changsha, Hunan, China, 410013)

Tel: 0731-89762609

Website: <http://www.zgzlyx.com>

Online First: <http://www.cnki.net>

E-mail: zgzlyx2011@163.com

WeChat Service Account:

AntiTumorPharmacy

Price: ¥30/Issue, ¥180/Year

Publishing Date:

Apr. 28, 2025

Basic Information of the Journal:

CN 43-1507/R*2011*B*A4*144* ZH*P*
¥30.00*19*2025-4

Prognostic value of systemic immune inflammation index/albumin ratio for NSCLC patients receiving opioids and immunotherapy

..... LEI Yan, LIU Yong 245

Analysis of risk factors of PD-1 inhibitor-associated thyroid adverse events based on propensity score matching

..... WANG Zhuqing, WU Yiqing, ZHU Zhonghua 252

Clinical observation of sorafenib combined with azacitidine and low-dose CHG regimen in the treatment of refractory/relapsed FLT3-ITD-positive AML

..... REN Xinxin, HAN Xiaohui, ZHAO Hongbo, et al. 259

Case Report

Anlotinib combined with AK105 in the treatment of relapsed small cell lung cancer after first-line therapy: a case report

..... BI Wenxin, DU Chao, LI Chenglin 264

A case of simultaneous primary bilateral breast cancer with different molecular subtypes and bone metastasis

..... HUANG Xiaohui, TANG Lin, ZHOU Wei, et al. 269

Nursing

Effect of IMB intervention model on secondary osteoporosis in postmenopausal breast cancer patients treated with aromatase inhibitor

..... ZHANG Gelin, WU Wei, SUN Yuan, et al. 275

Diagnostic agreement between GLIM criteria and PG-SGA in preoperative nutritional assessment of colorectal cancer patients: a prospective cohort analysis

..... SUN Wei, CHEN Pengchao, LUO Yue, et al. 283

• 特别声明 •

本刊作者文责自负,稿件一经采用,该文的复制权、发行权、信息网络传播权、汇编权等相关权利视为自动转让给本刊。本刊有权将上述权利转授给收录本刊的数据库,如作者不同意文章被转录,请来稿时注明,本刊将做适当处理。